Targeting Complement C3 via Intrathecal siRNA: A Novel Approach to Neuroinflammation in Neurodegeneration
Time: 4:00 pm
day: Day 1
Details:
- Early discovery and translational journey of Apellis’ siRNA program targeting complement C3 for neurodegenerative diseases
- Insights from siRNA screening and optimization to enable potent, durable knockdown of C3 in non-human primates (NHPs), setting the stage for clinical translation
- Exploring the potential of intrathecal complement inhibition as a first-line therapy and its synergistic use in combination with other disease modifying therapies
